Perspective Therapeutics, Inc. (CATX) stock
CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.75−0.03 (-3.85%)
Close on Nov 20, 2026Market cap $86.05MP/E –Yield –
Perspective Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Perspective Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $96.18M, up 72.2% year over year. For fiscal 2025 it was $84.22M, up 102.3% from the year before. Over ten years it grew 62.2% a year on average. The highest annual figure on record is $84.22M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $84.22M | +102.3% |
| FY2024 | Dec 31, 2024 | $41.64M | +4798.6% |
| FY2022 | Jun 30, 2022 | $850.00K | -40.4% |
| FY2021 | Jun 30, 2021 | $1.43M | +26.7% |
| FY2020 | Jun 30, 2020 | $1.13M | -23.6% |
| FY2019 | Jun 30, 2019 | $1.47M | -15.6% |
| FY2018 | Jun 30, 2018 | $1.75M | +80.9% |
| FY2017 | Jun 30, 2017 | $965.00K | +82.8% |
| FY2016 | Jun 30, 2016 | $528.00K | -14.1% |
| FY2015 | Jun 30, 2015 | $615.00K | -8.0% |
| FY2014 | Jun 30, 2014 | $668.80K | +6.6% |
| FY2013 | Jun 30, 2013 | $627.11K | -19.7% |
| FY2012 | Jun 30, 2012 | $780.58K | -20.4% |
| FY2011 | Jun 30, 2011 | $981.19K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $21.54M | +29.6% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $21.37M | +49.1% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $32.92M | +155.6% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $20.34M | +69.1% |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $16.62M | +79.2% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $14.33M | +92.3% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $12.88M | +1518.5% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $12.03M | +2090.9% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $9.28M | +1633.6% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $7.45M | +961.5% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $796.00K | +70.1% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $549.00K | +51.7% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $535.00K | +87.7% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $702.00K | +125.0% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $468.00K | +45.3% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $362.00K | +23.1% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $285.00K | +2.9% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $312.00K | +33.9% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $322.00K | -5.6% |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $294.00K | -1.7% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $277.00K | -33.1% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $233.00K | -44.5% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | $341.00K | -40.4% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $299.00K | -36.8% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $414.00K | +21.8% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $420.00K | +16.0% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $572.00K | +81.0% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $473.00K | +44.6% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $340.00K | +126.7% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $362.00K | +110.5% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $316.00K | +121.0% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $327.00K | +78.7% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $150.00K | +158.6% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $172.00K | +19.4% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $143.00K | -8.5% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $183.00K | +29.4% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $58.00K | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $144.00K | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $156.36K | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $141.40K | – |
See a number that looks wrong?